Lung involvement and drug-induced lung disease in patients with rheumatoid arthritis

References

• Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 358(9285), 903–911 (2001).
   PubMed Web of Science ®Google Scholar
• Atzeni F, Sarzi-Puttini P. Anti-cytokine antibodies for rheumatic diseases. Curr. Opin. Investig. Drugs 10(11), 1204–1211 (2009).
   PubMedGoogle Scholar
• Young A, Koduri G, Batley M et al.; Early Rheumatoid Arthritis Study (ERAS) group. Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. Rheumatology (Oxford) 46(2), 350–357 (2007).
   PubMed Web of Science ®Google Scholar
• Bilgici A, Ulusoy H, Kuru O, Celenk C, Unsal M, Danaci M. Pulmonary involvement in rheumatoid arthritis. Rheumatol. Int. 25(6), 429–435 (2005).
   PubMed Web of Science ®Google Scholar
• Brown KK. Rheumatoid lung disease. Proc. Am. Thorac. Soc. 4(5), 443–448 (2007).
   PubMedGoogle Scholar
• Turesson C, Jacobsson LT, Sturfelt G, Matteson EL, Mathsson L, Rönnelid J. Rheumatoid factor and antibodies to cyclic citrullinated peptides are associated with severe extra-articular manifestations in rheumatoid arthritis. Ann. Rheum. Dis. 66(1), 59–64 (2007).
   PubMed Web of Science ®Google Scholar
• Nyhäll-Wåhlin BM, Petersson IF, Nilsson JA, Jacobsson LT, Turesson C; BARFOT study group. High disease activity disability burden and smoking predict severe extra-articular manifestations in early rheumatoid arthritis. Rheumatology (Oxford) 48(4), 416–420 (2009).
   PubMed Web of Science ®Google Scholar
• Kim SK, Park SH, Shin IH, Choe JY. Anti-cyclic citrullinated peptide antibody, smoking, alcohol consumption, and disease duration as risk factors for extraarticular manifestations in Korean patients with rheumatoid arthritis. J. Rheumatol. 35(6), 995–1001 (2008).
   PubMed Web of Science ®Google Scholar
• Alexiou I, Germenis A, Koutroumpas A, Kontogianni A, Theodoridou K, Sakkas LI. Anti-cyclic citrullinated peptide-2 (CCP2) autoantibodies and extra-articular manifestations in Greek patients with rheumatoid arthritis. Clin. Rheumatol. 27(4), 511–513 (2008).
   PubMed Web of Science ®Google Scholar
• Aubart F, Crestani B, Nicaise-Roland P et al. High levels of anti-cyclic citrullinated peptide autoantibodies are associated with co-occurrence of pulmonary diseases with rheumatoid arthritis. J. Rheumatol. 38(6), 979–982 (2011).
   PubMed Web of Science ®Google Scholar
• Mori S, Koga Y, Sugimoto M. Small airway obstruction in patients with rheumatoid arthritis. Mod. Rheumatol. 21(2), 164–173 (2011).
   PubMed Web of Science ®Google Scholar
• Vergnenègre A, Pugnere N, Antonini MT et al. Airway obstruction and rheumatoid arthritis. Eur. Respir. J. 10(5), 1072–1078 (1997).
   PubMed Web of Science ®Google Scholar
• Hayakawa H, Sato A, Imokawa S, Toyoshima M, Chida K, Iwata M. Bronchiolar disease in rheumatoid arthritis. Am. J. Respir. Crit. Care Med. 154(5), 1531–1536 (1996).
   PubMed Web of Science ®Google Scholar
• Schwarz MI, Lynch DA, Tuder R. Bronchiolitis obliterans: the lone manifestation of rheumatoid arthritis? Eur. Respir. J. 7(4), 817–820 (1994).
   PubMed Web of Science ®Google Scholar
• Ascherman DP. Interstitial lung disease in rheumatoid arthritis. Curr. Rheumatol. Rep. 12(5), 363–369 (2010).
   PubMedGoogle Scholar
• Gochuico BR, Avila NA, Chow CK et al. Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch. Intern. Med. 168(2), 159–166 (2008).
   PubMedGoogle Scholar
• American Thoracic Society and European Respiratory Society. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of idiopathic interstitial pneumonias. Am. J. Respir. Crit. Care Med. 165, 277–304 (2002).
   PubMedGoogle Scholar
• Kim EJ, Collard HR, King TE Jr. Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern. Chest 136(5), 1397–1405 (2009).
   PubMed Web of Science ®Google Scholar
• Lee HK, Kim DS, Yoo B et al. Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. Chest 127(6), 2019–2027 (2005).
   PubMed Web of Science ®Google Scholar
• Wilson MS, Wynn TA. Pulmonary fibrosis: pathogenesis, etiology and regulation. Mucosal Immunol. 2(2), 103–121 (2009).
   PubMed Web of Science ®Google Scholar
• Rao RN, Goodman LR, Tomashefski JF Jr. Smoking-related interstitial lung disease. Ann. Diagn. Pathol. 12(6), 445–457 (2008).
   PubMed Web of Science ®Google Scholar
• Pardo A, Gibson K, Cisneros J et al. Up-regulation and profibrotic role of osteopontin in human idiopathic pulmonary fibrosis. PLoS Med. 2(9), e251 (2005).
   PubMed Web of Science ®Google Scholar
• Agostini C, Gurrieri C. Chemokine/cytokine cocktail in idiopathic pulmonary fibrosis. Proc. Am. Thorac. Soc. 3(4), 357–363 (2006).
   PubMedGoogle Scholar
• Dawson JK, Fewins HE, Desmond J, Lynch MP, Graham DR. Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests. Thorax 56(8), 622–627 (2001).
   PubMed Web of Science ®Google Scholar
• Tanaka N, Kim JS, Newell JD et al. Rheumatoid arthritis-related lung diseases: CT findings. Radiology 232(1), 81–91 (2004).
   PubMed Web of Science ®Google Scholar
• Akira M, Sakatani M, Hara H. Thin-section CT findings in rheumatoid arthritis-associated lung disease: CT patterns and their courses. J. Comput. Assist. Tomogr. 23(6), 941–948 (1999).
   PubMed Web of Science ®Google Scholar
• Biederer J, Schnabel A, Muhle C, Gross WL, Heller M, Reuter M. Correlation between HRCT findings, pulmonary function tests and bronchoalveolar lavage cytology in interstitial lung disease associated with rheumatoid arthritis. Eur. Radiol. 14(2), 272–280 (2004).
   PubMed Web of Science ®Google Scholar
• Inui N, Enomoto N, Suda T, Kageyama Y, Watanabe H, Chida K. Anti-cyclic citrullinated peptide antibodies in lung diseases associated with rheumatoid arthritis. Clin. Biochem. 41(13), 1074–1077 (2008).
   PubMed Web of Science ®Google Scholar
• Bongartz T, Cantaert T, Atkins SR et al. Citrullination in extra-articular manifestations of rheumatoid arthritis. Rheumatology (Oxford). 46(1), 70–75 (2007).
   PubMed Web of Science ®Google Scholar
• Atkins SR, Turesson C, Myers JL et al. Morphologic and quantitative assessment of CD20+ B cell infiltrates in rheumatoid arthritis-associated nonspecific interstitial pneumonia and usual interstitial pneumonia. Arthritis Rheum. 54(2), 635–641 (2006).
   PubMed Web of Science ®Google Scholar
• Turesson C, Matteson EL, Colby TV et al. Increased CD4+ T cell infiltrates in rheumatoid arthritis-associated interstitial pneumonitis compared with idiopathic interstitial pneumonitis. Arthritis Rheum. 52(1), 73–79 (2005).
   PubMed Web of Science ®Google Scholar
• Hamblin MJ, Horton MR. Rheumatoid arthritis-associated interstitial lung disease: diagnostic dilemma. Pulm. Med. 2011, 872120 (2011).
   PubMedGoogle Scholar
• Emery P. Early arthritis. In: Targeted Therapies in Rheumatology. Smolen JS, Lipsky PE (Eds). Martin Dunitz, London, UK, 509–513 (2003).
   Google Scholar
• Nell VP, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford). 43(7), 906–914 (2004).
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewé R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann. Rheum. Dis. 69(6), 964–975 (2010).
   PubMed Web of Science ®Google Scholar
• Caporali R, Pallavicini FB, Filippini M et al. Treatment of rheumatoid arthritis with anti-TNF-α agents: a reappraisal. Autoimmun. Rev. 8(3), 274–280 (2009).
   PubMed Web of Science ®Google Scholar
• Atzeni F, Benucci M, Sallì S, Bongiovanni S, Boccassini L, Sarzi-Puttini P. Different effects of biological drugs in rheumatoid arthritis. Autoimmun. Rev. 12(5), 575–579 (2013).
   PubMed Web of Science ®Google Scholar
• Atzeni F, Sarzi-Puttini P, Gorla R, Marchesoni A, Caporali R. Switching rheumatoid arthritis treatments: an update. Autoimmun. Rev. 10(7), 397–403 (2011).
   PubMed Web of Science ®Google Scholar
• Dawson JK, Graham DR, Desmond J, Fewins HE, Lynch MP. Investigation of the chronic pulmonary effects of low-dose oral methotrexate in patients with rheumatoid arthritis: a prospective study incorporating HRCT scanning and pulmonary function tests. Rheumatology (Oxford). 41(3), 262–267 (2002).
   PubMed Web of Science ®Google Scholar
• Herrinton LJ, Harrold LR, Liu L et al. Association between anti-TNF-α therapy and interstitial lung disease. Pharmacoepidemiol. Drug Saf. 22(4), 394–402 (2013).
   PubMed Web of Science ®Google Scholar
• Panopoulos ST, Sfikakis PP. Biological treatments and connective tissue disease associated interstitial lung disease. Curr. Opin. Pulm. Med. 17(5), 362–367 (2011).
   PubMed Web of Science ®Google Scholar
• Kremer JM, Alarcón GS, Weinblatt ME et al. Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum. 40(10), 1829–1837 (1997).
   PubMed Web of Science ®Google Scholar
• Suissa S, Hudson M, Ernst P. Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. Arthritis Rheum. 54(5), 1435–1439 (2006).
   PubMed Web of Science ®Google Scholar
• Goodwin SD, Glenny RW. Nonsteroidal anti-inflammatory drug-associated pulmonary infiltrates with eosinophilia. Review of the literature and Food and Drug Administration Adverse Drug Reaction reports. Arch. Intern. Med. 152(7), 1521–1524 (1992).
   PubMedGoogle Scholar
• Turner-Warwick M. Adverse reactions affecting the lung: possible association with D-penicillamine. J. Rheumatol. Suppl. 7, 166–168 (1981).
   PubMedGoogle Scholar
• Eastmond CJ. Diffuse alveolitis as complication of penicillamine treatment for rheumatoid arthritis. Br. Med. J. 1(6024), 1506 (1976).
   PubMed Web of Science ®Google Scholar
• Tomioka R, King TE Jr. Gold-induced pulmonary disease: clinical features, outcome, and differentiation from rheumatoid lung disease. Am. J. Respir. Crit. Care Med. 155(3), 1011–1020 (1997).
   PubMed Web of Science ®Google Scholar
• Chikura B, Sathi N, Lane S, Dawson JK. Variation of immunological response in methotrexate-induced pneumonitis. Rheumatology (Oxford) 47(11), 1647–1650 (2008).
   PubMed Web of Science ®Google Scholar
• Schnabel A, Herlyn K, Burchardi C, Reinhold-Keller E, Gross WL. Long-term tolerability of methotrexate at doses exceeding 15 mg per week in rheumatoid arthritis. Rheumatol. Int. 15(5), 195–200 (1996).
   PubMed Web of Science ®Google Scholar
• Beyeler C, Jordi B, Gerber NJ, Im Hof V. Pulmonary function in rheumatoid arthritis treated with low-dose methotrexate: a longitudinal study. Br. J. Rheumatol. 35(5), 446–452 (1996).
   PubMedGoogle Scholar
• Dayton CS, Schwartz DA, Sprince NL et al. Low-dose methotrexate may cause air trapping in patients with rheumatoid arthritis. Am. J. Respir. Crit. Care Med. 151(4), 1189–1193 (1995).
   PubMed Web of Science ®Google Scholar
• Saravanan V, Kelly CA. Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis. Rheumatology (Oxford). 43(2), 143–147 (2004).
   PubMed Web of Science ®Google Scholar
• Alarcón GS, Kremer JM, Macaluso M et al. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Ann. Intern. Med. 127(5), 356–364 (1997).
   PubMed Web of Science ®Google Scholar
• Golden MR, Katz RS, Balk RA, Golden HE. The relationship of preexisting lung disease to the development of methotrexate pneumonitis in patients with rheumatoid arthritis. J. Rheumatol. 22(6), 1043–1047 (1995).
   PubMed Web of Science ®Google Scholar
• Imokawa S, Colby TV, Leslie KO, Helmers RA. Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. Eur. Respir. J. 15(2), 373–381 (2000).
   PubMed Web of Science ®Google Scholar
• Salaffi F, Manganelli P, Carotti M, Subiaco S, Lamanna G, Cervini C. Methotrexate-induced pneumonitis in patients with rheumatoid arthritis and psoriatic arthritis: report of five cases and review of the literature. Clin. Rheumatol. 16(3), 296–304 (1997).
   PubMed Web of Science ®Google Scholar
• Cottin V, Tébib J, Massonnet B, Souquet PJ, Bernard JP. Pulmonary function in patients receiving long-term low-dose methotrexate. Chest 109(4), 933–938 (1996).
   PubMed Web of Science ®Google Scholar
• Carson CW, Cannon GW, Egger MJ, Ward JR, Clegg DO. Pulmonary disease during the treatment of rheumatoid arthritis with low dose pulse methotrexate. Semin. Arthritis Rheum. 16(3), 186–195 (1987).
   PubMed Web of Science ®Google Scholar
• McCurry J. Japan deaths spark concerns over arthritis drug. Lancet 363, 461 (2004).
   PubMed Web of Science ®Google Scholar
• Chakravarty K, McDonald H, Pullar T et al.; British Society for Rheumatology, British Health Professionals in Rheumatology Standards, Guidelines and Audit Working Group; British Association of Dermatologists (BAD). BSR/BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists. Rheumatology (Oxford) 47(6), 924–925 (2008).
   PubMed Web of Science ®Google Scholar
• Chikura B, Lane S, Dawson JK. Clinical expression of leflunomide-induced pneumonitis. Rheumatology (Oxford) 48(9), 1065–1068 (2009).
   PubMed Web of Science ®Google Scholar
• Atzeni F, Talotta R, Salaffi F et al. Immunogenicity and autoimmunity during anti-TNF therapy. Autoimmun. Rev. 12(7), 703–708 (2013).
   PubMed Web of Science ®Google Scholar
• Dascalu C, Mrejen-Shakin K, Bandagi S. Adalimumab-induced acute pneumonitis in a patient with rheumatoid arthritis. J. Clin. Rheumatol. 16(4), 172–174 (2010).
   PubMed Web of Science ®Google Scholar
• Huggett MT, Armstrong R. Adalimumab-associated pulmonary fibrosis. Rheumatology (Oxford) 45(10), 1312–1313 (2006).
   PubMed Web of Science ®Google Scholar
• Taki H, Kawagishi Y, Shinoda K et al. Interstitial pneumonitis associated with infliximab therapy without methotrexate treatment. Rheumatol. Int. 30(2), 275–276 (2009).
   PubMed Web of Science ®Google Scholar
• Cho SK, Oh IH, Park CK, Bae SC, Sung YK. Etanercept induced organizing pneumonia in a patient with rheumatoid arthritis. Rheumatol. Int. 1007, 1350–1354 (2010).
   Google Scholar
• Yamazaki H, Isogai S, Sakurai T, Nagasaka K. A case of adalimumab-associated interstitial pneumonia with rheumatoid arthritis. Mod. Rheumatol. 20(5), 518–521 (2010).
   PubMed Web of Science ®Google Scholar
• Jackson RM, Fell CD. Etanercept for idiopathic pulmonary fibrosis: lessons on clinical trial design. Am. J. Respir. Crit. Care Med. 178(9), 889–891 (2008).
   PubMed Web of Science ®Google Scholar
• Schoe A, van der Laan-Baalbergen NE, Huizinga TW, Breedveld FC, van Laar JM. Pulmonary fibrosis in a patient with rheumatoid arthritis treated with adalimumab. Arthritis Rheum. 55(1), 157–159 (2006).
   PubMed Web of Science ®Google Scholar
• Atzeni F, Sarzi-Puttini P. Twelve years’ experience with etanercept in the treatment of rheumatoid arthritis: how it has changed clinical practice. Expert Rev. Clin. Immunol. 8(3), 213–222 (2012).
   PubMed Web of Science ®Google Scholar
• Dixon WG, Hyrich KL, Watson KD, Lunt M, Symmons DP; BSRBR Control Centre Consortium; British Society for Rheumatology Biologics Register. Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register. Ann. Rheum. Dis. 69(6), 1086–1091 (2010).
   PubMed Web of Science ®Google Scholar
• Perez-Alvarez P, Perez-de-Lis M, Diaz-Lagares C et al. Interstitial lung disease induced or exacerbated by TNF targeted therapies: analysis of 122 cases. Sem. Arthritis Rheum. 41, 256–264 (2011).
   PubMed Web of Science ®Google Scholar
• Koike T, Harigai M, Ishiguro N et al. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients. Mod. Rheumatol. 22(4), 498–508 (2012).
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Tatsuki Y, Nogami Y et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann. Rheum. Dis. 67(2), 189–194 (2008).
   PubMed Web of Science ®Google Scholar
• Bargagli E, Galeazzi M, Rottoli P. Infliximab treatment in a patient with rheumatoid arthritis and pulmonary fibrosis. Eur. Respir. J. 24(4), 708 (2004).
   PubMed Web of Science ®Google Scholar
• Vassallo R, Matteson E, Thomas CF Jr. Clinical response of rheumatoid arthritis-associated pulmonary fibrosis to tumor necrosis factor-α inhibition. Chest 122(3), 1093–1096 (2002).
   PubMedGoogle Scholar
• Antoniou KM, Mamoulaki M, Malagari K et al. Infliximab therapy in pulmonary fibrosis associated with collagen vascular disease. Clin. Exp. Rheumatol. 25(1), 23–28 (2007).
   PubMed Web of Science ®Google Scholar
• Miyazaki Y, Araki K, Vesin C et al. Expression of a tumor necrosis factor-α transgene in murine lung causes lymphocytic and fibrosing alveolitis. A mouse model of progressive pulmonary fibrosis. J. Clin. Invest. 96(1), 250–259 (1995).
   PubMed Web of Science ®Google Scholar
• Sullivan DE, Ferris M, Nguyen H, Abboud E, Brody AR. TNF-α induces TGF-β1 expression in lung fibroblasts at the transcriptional level via AP-1 activation. J. Cell. Mol. Med. 13(8B), 1866–1876 (2009).
   PubMed Web of Science ®Google Scholar
• Kouba DJ, Chung KY, Nishiyama T et al. Nuclear factor-kB mediates TNF-α inhibitory effect on α 2(I) collagen (COL1A2) gene transcription in human dermal fibroblasts. J. Immunol. 162(7), 4226–4234 (1999).
   PubMed Web of Science ®Google Scholar
• Atzeni F, Doria A, Turiel M, Maurizio T, Sarzi-Puttini P. What is the role of rituximab in the treatment of rheumatoid arthritis? Autoimmun. Rev. 6(8), 553–558 (2007).
   PubMed Web of Science ®Google Scholar
• Wagner SA, Mehta AC, Laber DA. Rituximab-induced interstitial lung disease. Am. J. Hematol. 82(10), 916–919 (2007).
   PubMed Web of Science ®Google Scholar
• Dass S, Atzeni F, Vital E et al. Safety of rituximab in patients with rheumatoid arthritis and concomitant lung disease. Annals Rheum. Dis. Abstract OP0016 (2001).
   Google Scholar
• Popa C, Leandro MJ, Cambridge G, Edwards JC. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs. Rheumatology (Oxford) 46(4), 626–630 (2007).
   PubMed Web of Science ®Google Scholar
• Matteson EL, Bongartz T, Ryu JH, Crowson CS, Hartman TE, Dellaripa PF. Open-label, pilot study of the safety and clinical effects of rituximab in patients with rheumatoid arthritis-associated interstitial pneumonia. Open J. Rheumatol. Autoimmun. Dis. 2, 53–58 (2012).
   Google Scholar
• Atzeni F, Sarzi-Puttini P, Mutti A, Bugatti S, Cavagna L, Caporali R. Long-term safety of abatacept in rheumatoid arthritis. Autoim. Rev. (2013).
   Google Scholar
• Nannini C, Ryu JH, Matteson EL. Lung disease in rheumatoid arthritis. Curr. Opin. Rheumatol. 20(3), 340–346 (2008).
   PubMed Web of Science ®Google Scholar
• Kaneko A. Tocilizumab in rheumatoid arthritis: efficacy, safety and its place in therapy. Ther. Adv. Chronic Dis. 4(1), 15–21 (2013).
   PubMedGoogle Scholar
• Kawashiri SY, Kawakami A, Sakamoto N, Ishimatsu Y, Eguchi K. A fatal case of acute exacerbation of interstitial lung disease in a patient with rheumatoid arthritis during treatment with tocilizumab. Rheumatol. Int. 32(12), 4023–4026 (2012).
   PubMed Web of Science ®Google Scholar
• Swigris JJ, Olson AL, Fischer A et al. Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest 130(1), 30–36 (2006).
   PubMed Web of Science ®Google Scholar
• Saketkoo LA, Espinoza LR. Rheumatoid arthritis interstitial lung disease: mycophenolate mofetil as an antifibrotic and disease-modifying antirheumatic drug. Arch. Intern. Med. 168(15), 1718–1719 (2008).
   PubMed Web of Science ®Google Scholar
• Chang HK, Park W, Ryu DS. Successful treatment of progressive rheumatoid interstitial lung disease with cyclosporine: a case report. J. Korean Med. Sci. 17(2), 270–273 (2002).
   PubMed Web of Science ®Google Scholar
• Ogawa D, Hashimoto H, Wada J et al. Successful use of cyclosporin A for the treatment of acute interstitial pneumonitis associated with rheumatoid arthritis. Rheumatology (Oxford) 39(12), 1422–1424 (2000).
   PubMed Web of Science ®Google Scholar
• Mohr M, Jacobi AM. Interstitial lung disease in rheumatoid arthritis: response to IL-6R blockade. Scand. J. Rheumatol. 40(5), 400–401 (2011).
   PubMed Web of Science ®Google Scholar
• Volpicelli G. Lung sonography. J. Ultrasound Med. 32(1), 165–171 (2013).
   PubMed Web of Science ®Google Scholar